Premarket trading brought sharp moves across several high-profile stocks as investors digested trial updates in biotech, analyst rating changes in defense, and operational risks in medical devices and fitness. Roivant Sciences surged, while Novartis and Peloton fell on clinical trial and research-driven sentiment, and Boston Scientific weighed on results outlook tied to a cyber incident. Lockheed Martin edged higher after an upgrade pointed to earnings growth momentum.
Key takeaways
- Roivant Sciences rose 24% after Phase 2 results for subsidiary Pulmovant’s mosliciguat showed a placebo-adjusted reduction in pulmonary vascular resistance in pulmonary hypertension with interstitial lung disease.
- Novartis fell 12% after Phase 3 data for del-desiran showed no significant improvement in myotonic dystrophy type 1.
- Peloton dropped more than 4% following a Morgan Stanley downgrade to underweight, citing structural headwinds in fitness.
- Boston Scientific slipped over 2% after the company said a recent cyberattack could affect 2026 sales and profit targets.
- Lockheed Martin rose 0.7% after UBS upgraded the stock to buy, citing underappreciated earnings growth potential.
What drove the biggest premarket moves
Roivant Sciences climbed 24% after the company reported Phase 2 results for Pulmovant’s mosliciguat. The disclosure said the treatment produced “a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance” in patients with pulmonary hypertension with interstitial lung disease. For investors, the key swing factor was the reported magnitude and statistical significance versus placebo adjustment, which can meaningfully shift expectations for subsequent trials and potential regulatory prospects.
Novartis slid 12% as Phase 3 results for del-desiran failed to show a significant improvement for patients with myotonic dystrophy type 1. The study’s outcome—no “significant improvement”—is typically interpreted by markets as a setback for efficacy and can increase the probability of slower development timelines or higher hurdle requirements for future programs, particularly in late-stage assets where expectations are already high.
Peloton Interactive dropped more than 4% after a Morgan Stanley downgrade from equal weight to underweight. The firm cited “structural headwinds in fitness,” a framing that tends to emphasize challenges that may not be solved quickly through near-term promotions or product cycles. Downgrades like this can weigh on sentiment even without new company-specific operational deterioration, because they reshape how analysts model medium-term demand and profitability.
Boston Scientific declined more than 2% after the medical device maker said a recent cyberattack likely affected sales and profit targets for 2026. In practical terms, investors were focused on the risk to forward guidance—how disruptions to systems, processes, or customer workflows could translate into delayed orders, slower conversions, or incremental costs. Cyber incidents are increasingly treated by markets as both an operational and a reputational risk until impacts are quantified.
Lockheed Martin rose 0.7% following an UBS upgrade to buy from neutral. UBS pointed to underappreciated earnings growth potential, suggesting the bank believes consensus expectations may be too conservative regarding how growth and margins could evolve. Analyst upgrades often move shares in the near term by changing the distribution of expectations among institutional investors, especially when they come with a clear thesis around earnings delivery.
Market reaction: investors priced in clinical outcomes and forward risk
The premarket tape showed a clear split between biotech-driven repricing and sell-side and operational risk adjustments. Roivant’s gains contrasted sharply with Novartis’s pullback, reflecting how investors quickly translate trial endpoints into probabilities of future regulatory and commercial success. In late-stage development, “no significant improvement” typically leads to immediate repricing because it can reduce the likelihood that a program will clear upcoming decision points.
Meanwhile, Peloton’s decline and Boston Scientific’s slide reflected non-trial catalysts. For Peloton, a downgrade based on “structural headwinds” indicates that investors were responding to an updated risk assessment around category dynamics and demand resilience. For Boston Scientific, the market response centered on the forward financial implications of a cyberattack, with uncertainty likely increasing around 2026 revenue capture and margin delivery until management provides more detail on scope and remediation.
Lockheed Martin’s modest rise stood out as comparatively steady versus the larger swings in biotech and consumer health. The UBS upgrade suggested incremental confidence in earnings outlook rather than a major change in company-specific fundamentals.
What to watch next
Investors will likely focus on follow-through milestones for the companies tied to clinical data, including any planned next-stage study updates and how management discusses endpoint relevance. For Peloton and Boston Scientific, attention should turn to whether additional disclosures clarify the timeline of recovery or cost implications—particularly for the cyberattack’s impact on 2026 targets. For Lockheed Martin, investors may look for confirmation through upcoming disclosures and how UBS’s earnings growth thesis aligns with broader defense-sector expectations. In the near term, broader market focus will remain on upcoming macro and policy data, which can influence discount rates and risk appetite across growth and healthcare sectors.
